Collagen Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Collagen is the most abundant protein found in the animal kingdom. It is produced by the fibroblasts and is a structural protein. 28 types of collagens are known, with type 1 accounting for about 90% of the collagen in the human body. Structurally it is a triple-helix composed of 3 amino acids, namely Glycine, Proline, and Hydroxyproline. Collagen is present in many parts of the human body and is found in the connective tissues, bones, cartilage, tendons, ligaments, and skin. It has many roles in the human body, including many cellular processes like cellular communication, cellular migration, tissue repair, and immune response. There are many sources of collagen, including animal skin, bones and ligaments, and seafood.  Collagen supplements are also available in the market for consumption in deficient people. It is used for many indications, so companies are trying to find new and novel molecules to prevent and cure diseases. The development and launch of newer products by the market players will significantly enhance the revenue of the Collagen market over the forecast years. Peyronie’s disease (PD) is a connective tissue disorder in which plaque forms in the Tunica Albuginea layer beneath the skin of the penis resulting in the bending of the penis and causing a painful erection. According to a research article, the prevalence rates ranging between 0.4% to 20.3% are present with considerable variation depending upon age, color, race, and co-morbidities. Thus, there is an opportunity for the market players in the market.

Several of these inhibitors are on the market, while many are in ongoing clinical trials. Various companies have various products in their pipelines, with 21 products in various stages of clinical trials. 2 products in Phase 4, 1 product in Phase 3, 7 products in Phase 2, and 1 product in Phase 1 of the clinical trials.

Approved molecules

• Xiaflex (collagenase clostridium histolyticum)
• Rizaben (tranilast)

Drugs in Pipeline

• Fezagepras (PBI-4050)
• Hydronidone (F351)
• Aerodone (Aerosol Pirfenidone)
• PTR-01
• TPX-100
• Tempostatin (Halofuginone)
• Deuterium Pirfenidone (LYT-100)
• Remlarsen (MRG-201)
• Pirfenidone Inhalation (S-770108 Inhalation)

Clinical Activity and Developments of Collagen

As of June 2023, various companies have approximately 21 products for 228 diseases. For these diseases, many trials are being conducted by players globally. For instance,

• In March 2022, Datum Dental Ltd completed a Phase 4 clinical trial to study the histological evaluation of healing following Ridge preservation using a composite bovine-derived xenograft or a Hydroxyapatite Collagen Matrix.
• In December 2020, Men’s Health Boston completed a Phase 4 clinical pilot study to study the effect of testosterone treatment in patients who are undergoing Xiaflex therapy for the treatment of Peyronie’s Disease.
• In August 2020, Hasanuddin University completed a Phase 4 clinical trial to study the Prolotherapy intervention effect in patients with Knee Osteoarthritis.
• In March 2020, Yonsei University completed a Phase 4 clinical trial to study the Collagen-thrombin Matrix efficacy during cardiac surgery.